Anax Pharma Private Limited - Due diligence report
A 360° intelligence report on Anax Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals - …
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Anax Pharma — 360° Intelligence Report
Generated from MCA filings & public recordsAnax Pharma is assessed as Low Risk with a Trust Score of 85/100. Anax Pharma is an active private limited indian non-government company incorporated in 2012, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 23 Nov 2026 from the latest processed filings. Anax Pharma Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
Score Card
Higher is safer · rule-based & explainableFinancial Intelligence Dashboard
Standalone · 0 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
Credit & Compliance Intelligence
Why the scores are what they are- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
Charges position: 0 open ( 48.0 cr ) · 0 satisfied ( 12.5 cr ).
- Company status is Active as per MCA.
- Last balance sheet is for Mar 2023 - filings overdue.
- 1 active GST registration(s).
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| HUKMARAM CHOUDHARY | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| GHAN MISHRA SHYAM | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
Ownership & Group Intelligence
As per FY 2023 annual returnPromoters hold a dominant controlling stake - exact percentages are part of the full report.
Key managerial personnel: HUKMARAM CHOUDHARY (Managing Director)
Full shareholding pattern, group structure & capital events →
Risk Intelligence Center
Growth 95 · Distress 70Stakeholder Verdicts
Vendor · Banker · Investor- Statutory record is clean.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance record supports lending.
- 5 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
MCA Filings & Events Timeline
Latest 5 eventsKey Observations
Auto-generated from the data above| Company | CIN | Location |
|---|---|---|
| Divit Nutraceuticals | U51900UP2013PTC121147 | Ghaziabad, Uttar Pradesh, India |
| Swaranimakash Life Sciences Private Limited | U74999UR2018PTC008988 | Dehradun, Uttarakhand, India |
| Narsimha Colorchem Private Limited | U24290UP2021PTC157563 | Mathura, Uttar Pradesh, India |
| Hapchem Private Limited | U24290GJ2022PTC129872 | Kalol, Gujarat, India |
| Mangalam Dyechem Private Limited | U74899DL1983PTC015055 | Delhi, Delhi, India |
| Pancoat Paints India Limited | U24129RJ2020PLC069506 | Jaipur, Rajasthan, India |
| Blackbryont Pharmaceuticals Private Limited | U24232KL2009PTC024806 | Ernakulam, Kerala, India |
| Anamol Laboratories Private Limited | U85195MH1998PTC154272 | Palghar, Maharashtra, India |
Who Uses This Report
CA · CS · Banker · Investor · VendorVerify Anax Pharma before audits and certifications: compliance score 75/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Track statutory health of Anax Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Anax Pharma - screening before a deeper diligence.
Vendor verdict: Favourable indicators. Trust score 85/100, distress signals and MSME payment-delay disclosures - know whether Anax Pharma pays its suppliers before you extend credit terms.
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Anax Pharma - groundwork for KYC, onboarding and disputes.
Frequently Asked Questions
Is Anax Pharma an active company?
Anax Pharma has MCA status “Active” with a compliance score of 75/100 (Low Risk).
Is Anax Pharma financially healthy?
Anax Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Anax Pharma?
Its overall Trust Score is 85/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Anax Pharma?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.
Does Anax Pharma have loans or charges against its assets?
No charges are registered against this company - an unencumbered balance sheet.
Is Anax Pharma up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 75/100 (Low Risk).
Is it risky to lend to Anax Pharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.